Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2024; 15(9): 1847-1852
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1847
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1847
Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy?
Saeed Mohammadi, Ahmed Al-Harrasi, Natural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman
Ahmed Al-Harrasi, Department of Biological Sciences and Chemistry, University of Nizwa, Nizwa 616, Oman
Author contributions: Mohammadi S and Al-Harrasi A designed the overall concept and outline of the manuscript, and contributed to writing and editing the manuscript, illustrations, and review of the literature.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ahmed Al-Harrasi, PhD, Full Professor, Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, PO Box 33, Nizwa 616, Oman.
Received: April 1, 2024
Revised: May 13, 2024
Accepted: June 13, 2024
Published online: September 15, 2024
Processing time: 148 Days and 10.4 Hours
Revised: May 13, 2024
Accepted: June 13, 2024
Published online: September 15, 2024
Processing time: 148 Days and 10.4 Hours
Core Tip
Core Tip: Targeting macrophage function could be introduced as a new approach for managing diabetic cardiomyopathy. Chronic hyperglycemia interrupts the balance between pro-inflammatory and anti-inflammatory subtypes of macrophages, promoting inflammation and tissue damage. The dipeptidyl peptidase-4 inhibitors, used for diabetes, might offer cardioprotective benefits by influencing macrophage activity and promoting an anti-inflammatory environment.